Related Experiment Videos
[Recombinant protein folding and production].
Jean-Michel Betton1, Alain Chaffotte
1Unité de repliement et modélisation des protéines, Institut Pasteur, Paris, France. jmbetton@pasteur.fr
Medecine Sciences : M/S
|June 30, 2005
Summary
Controlling cellular expression conditions is key to preventing recombinant protein aggregation. Developing high-throughput genetic screens can monitor and improve protein folding for biopharmaceutical production.
Area of Science:
- Biotechnology
- Molecular Biology
- Biochemistry
Context:
- Industrial protein pharmaceuticals represent an advanced stage in recombinant protein production.
- Recombinant protein production frequently faces challenges with protein folding within cells.
- Misfolded proteins often aggregate into biologically inactive states, hindering therapeutic applications.
Purpose:
- To explore strategies for minimizing protein aggregation during recombinant protein production.
- To highlight the limitations of in vitro renaturation techniques.
- To advocate for in-cell expression condition control for improved protein folding.
Summary:
- Recombinant protein production, while advanced, is hampered by intracellular protein misfolding and aggregation.
- In vitro refolding of aggregated proteins is empirical and inefficient.
- Optimizing cellular expression conditions to promote proper protein folding is a more effective approach.
Impact:
- Improved methods for producing active recombinant proteins in their native state.
- Potential for more efficient and cost-effective biopharmaceutical manufacturing.
- Advancement of genetic screening tools for monitoring protein folding in real-time.